Potential effective treatment of shortening continuous erythropoietin receptor activator treatment interval combined with iron supplementation in hemodialysis patients

• Glavni autori: Yuki Kawai (Autor), Yoshiyuki Toya (Autor), Hiromichi Wakui (Autor), Tetsuya Fujikawa (Autor), Eiko Ueda (Autor), Kengo Azushima (Autor), Sho Kinguchi (Autor), Hiroshi Mitsuhashi (Autor), Tomoyuki Kawano (Autor), Tadashi Kuji (Autor), Satoshi Yamaguchi (Autor), Toshimasa Ohnishi (Autor), Kouichi Tamura (Autor)
• Format: Knjiga
• Izdano: Elsevier, 2021-09-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Our previous randomized controlled trial comparing the total dose of weekly versus biweekly continuous erythropoietin receptor activator (CERA) therapy to maintain optimal hemoglobin (Hb) levels showed no significant differences between the two therapies. This post-hoc analysis assessed whether the...